海正药业子公司省医药公司100%股权转让公开挂牌

Core Viewpoint - The company, Haizheng Pharmaceutical, announced the intention to transfer 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., through a public listing on a property trading platform, with an assessed value of 392.23 million yuan and a proposed starting price of 430 million yuan [1]. Group 1 - Haizheng Pharmaceutical submitted the application for the equity transfer on November 10, 2023, and the official listing period is from November 11 to December 8, 2023 [1]. - The assessed value of the subsidiary's 100% equity is 392.23 million yuan, while the proposed public listing starting price is set at 430 million yuan [1].